For adults struggling with weight, a weekly injection of tirzepatide offers real hope. Recent findings presented at the ...

Tirzepatide was associated with better glycemic control and weight loss outcomes than semaglutide and insulin among patients with T2D.

New research shows that people who take the weight-loss drug tirzepatide can keep most of the weight off for at least three ...

This new analysis focuses on 700 of these participants (64% females, average age 48 years) randomised to receive tirzepatide (5, 10, or 15 mg) who were treatment adherent (at least 75% doses ...

The dosage range of tirzepatide is 2.5mg to 15mg, taken once weekly as a subcutaneous injection. Tirzepatide has the highest ...

Medication doses were gradually increased to 15 mg for tirzepatide or 4.5 mg for dulaglutide, or to the highest maximum dose a participant could tolerate. The study’s primary and secondary ...

The original SURMOUNT-1 trial was published in NEJM in 2022, and found that, across 72 weeks, participants with obesity treated with 5 mg, 10 mg, or 15 mg of tirzepatide once weekly experienced ...

Eli Lilly's latest clinical readout for dual GIP/GLP-1 agonist tirzepatide is a big one, with data suggesting the drug can reduce the risk of developing type 2 diabetes in overweight and obese ...

INDIANAPOLIS – The way people are accessing GLP-1 medications Semaglutide and Tirzepatide is going to become very limited after the drugs were taken off the FDA’s shortage list. Hundreds of ...

Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both ...

Get Instant Summarized Text (Gist) Tirzepatide, a dual-incretin, was evaluated for its effects on cardiovascular and kidney biomarkers in overweight and obese adults with type 1 diabetes. Over 21 ...

Last week marked the FDA's deadline for compounders to stop making the obesity drug tirzepatide (Zepbound), leaving some patients unsure where to turn next. (NPR) Dexcom's investigational 15-day ...